ALIM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALIM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Alimera Sciences's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.12. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.57.
Alimera Sciences's EPS (Basic) for the three months ended in Mar. 2024 was $-0.12. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.57.
Alimera Sciences's EPS without NRI for the three months ended in Mar. 2024 was $-0.12. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.85.
During the past 3 years, the average EPS without NRIGrowth Rate was 19.30% per year.
During the past 13 years, Alimera Sciences's highest 3-Year average EPS without NRI Growth Rate was 72.30% per year. The lowest was -59.80% per year. And the median was 20.70% per year.
The historical data trend for Alimera Sciences's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alimera Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Earnings per Share (Diluted) | Get a 7-Day Free Trial | -2.19 | -1.04 | -0.66 | -2.59 | -0.84 |
Alimera Sciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Earnings per Share (Diluted) | Get a 7-Day Free Trial | -0.71 | -1.32 | -0.06 | -0.07 | -0.12 |
For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's PE Ratio distribution charts can be found below:
* The bar in red indicates where Alimera Sciences's PE Ratio falls into.
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Alimera Sciences's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as
Diluted Earnings Per Share (A: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-20.132 | - | 1.259) | / | 25.562 | |
= | -0.84 |
Alimera Sciences's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as
Diluted Earnings Per Share (Q: Mar. 2024 ) | = | (Net Income | - | Preferred Dividends | / | Shares Outstanding (Diluted Average) |
= | (-6.251 | - | 0) | / | 54.357 | |
= | -0.11 |
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.57
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
Alimera Sciences (NAS:ALIM) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Alimera Sciences's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Margaret Pax | director | 6310 TOWN SQUARE, SUITE 400, ALPHARETTA GA 30005 |
John Snisarenko | director | C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005 |
Pizzo Peter J. Iii | director | 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005 |
Erin Parsons | director | 97 WILLISTON RD, BROOKLINE MA 02445 |
Caligan Partners Lp | 10 percent owner | 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022 |
Ross D Demont | director | 51 PICKWICK ROAD, NEWTON MA 02465 |
C. Daniel Myers | other: Chairman Emeritus | 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005 |
David Edward Johnson | 10 percent owner | 590 MADISON AVENUE, NEW YORK NY 10022 |
Velan Capital Master Fund Lp | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Velan Capital Management Llc | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Velan Capital Holdings Llc | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Adam Morgan | director | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Velan Capital Investment Management Lp | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Velan Capital Spv I Llc | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Balaji Venkataraman | 10 percent owner | FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076 |
From GuruFocus
By Marketwired • 10-16-2023
By PurpleRose PurpleRose • 08-09-2022
By Ds*** Ds*** • 08-31-2022
By Value_Insider Value_Insider • 11-02-2022
By sperokesalga sperokesalga • 03-27-2023
By sperokesalga sperokesalga • 03-24-2023
By Marketwired • 08-02-2023
By sperokesalga sperokesalga • 05-08-2023
By Marketwired • 10-11-2023
By GuruFocus Research • 08-04-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.